Overview

Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2026-01-15

Target enrollment:

Participant gender:

Summary

This phase I/II trial studies the side effects of bomedemstat and maintenance immunotherapy with atezolizumab and to see how well they work in treating patients with newly diagnosed extensive stage small cell lung cancer. Bomedemstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving bomedemstat and atezolizumab may work better in treating patients with extensive stage small cell lung cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Washington

Collaborators:

Imago BioSciences,Inc.
National Cancer Institute (NCI)

Treatments:

Antibodies, Monoclonal
Atezolizumab
Immunoglobulin G
Immunoglobulins